Papers
7
Total Citations
123
H-Index
4
About
Chul Ahn is a radiation oncologist whose research has focused primarily on advancing stereotactic body radiation therapy (SBRT) techniques for early-stage breast cancer, with additional contributions to hypofractionated radiotherapy for laryngeal cancer. His most significant body of work centers on stereotactic partial breast irradiation (S-PBI), pioneering both 5-fraction and single-fraction treatment approaches as alternatives to conventional whole-breast or partial-breast irradiation following lumpectomy. His landmark 2017 phase 1 dose-escalation trial exploring 5-fraction S-PBI has garnered 66 citations, establishing foundational safety and dosimetry data that informed subsequent multi-institutional investigations. Ahn expanded this work into multicenter collaborative trials and cosmetic outcome assessments, demonstrating that stereotactic approaches can achieve favorable cosmetic results alongside acceptable tolerability profiles. His progression from single-institution phantom studies through prospective multicenter phase 1 trials reflects a rigorous translational research methodology, systematically bridging technical development and clinical application. By championing robotic stereotactic radiation delivery systems in breast cancer treatment, Ahn has contributed meaningfully to the evolving landscape of abbreviated radiation regimens, potentially improving patient convenience, reducing treatment burden, and broadening access to precision radiotherapy for women with early-stage disease.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7